Advanced Clear Cell Renal Cell Carcinoma clinical trials

Explore recruiting advanced clear cell renal cell carcinoma clinical trials.

Recruiting advanced clear cell renal cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Clear Cell Renal Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Belgium, France, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Italy, Spain, Romania, Germany, Netherlands, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Germany, France, Denmark, Sweden, Finland, Romania +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Czechia, Spain, Belgium, France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Clear Cell Renal Cell Carcinoma trials by city

Advanced Clear Cell Renal Cell Carcinoma in Toronto Advanced Clear Cell Renal Cell Carcinoma in Vancouver Advanced Clear Cell Renal Cell Carcinoma in Montreal Advanced Clear Cell Renal Cell Carcinoma in Calgary Advanced Clear Cell Renal Cell Carcinoma in Edmonton Advanced Clear Cell Renal Cell Carcinoma in Ottawa Advanced Clear Cell Renal Cell Carcinoma in Winnipeg Advanced Clear Cell Renal Cell Carcinoma in Quebec City Advanced Clear Cell Renal Cell Carcinoma in Hamilton Advanced Clear Cell Renal Cell Carcinoma in Kitchener Advanced Clear Cell Renal Cell Carcinoma in London Advanced Clear Cell Renal Cell Carcinoma in Halifax Advanced Clear Cell Renal Cell Carcinoma in New York Advanced Clear Cell Renal Cell Carcinoma in Los Angeles Advanced Clear Cell Renal Cell Carcinoma in Chicago Advanced Clear Cell Renal Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease